Does Rallies show Form 4 insider transactions for AVXL?

Yes. Rallies tracks AVXL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is AVXL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVXL. It does not provide personalized investment advice.

AVXL (Anavex Life Sciences) Stock Analysis - Insider Trades

Anavex Life Sciences (AVXL) is a publicly traded Healthcare sector company. As of May 21, 2026, AVXL trades at $2.75 with a market cap of $266.89M and a P/E ratio of -4.95. AVXL moved +3.00% today. Year to date, AVXL is -30.38%; over the trailing twelve months it is -63.48%. Its 52-week range spans $2.61 to $14.44. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces AVXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AVXL stock inside the company?

Recent AVXL insider activity includes Donhauser Peter D.O. bought 2.83K, Thomas Steffen bought 5.00K, MISSLING CHRISTOPHER U sold 73.38K, MISSLING CHRISTOPHER U sold 268.00K, and Skarpelos Athanasios sold 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AVXL Key Metrics

Key financial metrics for AVXL
Metric	Value
Price	$2.75
Market Cap	$266.89M
P/E Ratio	-4.95
EPS	$-0.54
Dividend Yield	0.00%
52-Week High	$14.44
52-Week Low	$2.61
Volume	0
Avg Volume	0
Revenue (TTM)	$4.68M
Net Income	$-46.38M
Gross Margin	0.00%

Recent AVXL Insider Trades

Donhauser Peter D.O. bought 2.83K (~$10.32K) on Jun 14, 2024.
Thomas Steffen bought 5.00K (~$22.60K) on May 15, 2024.
MISSLING CHRISTOPHER U sold 73.38K (~$374.97K) on Mar 28, 2024.
MISSLING CHRISTOPHER U sold 268.00K (~$2.14M) on Jun 28, 2023.
Skarpelos Athanasios sold 50.00K (~$453.00K) on May 25, 2022.

Latest AVXL News

Anavex Names Interim CEO Kellmeyer, Signals Q1 Filing Delay — May 6, 2026
Anavex submits new FDA data and advances EMA dialogue on blarcamesine — Mar 30, 2026
Blarcamesine Preserves Brain Volume and Saves 17.8 Months in Alzheimer’s Trial — Mar 23, 2026
Autophagy Failure Implicated in Alzheimer’s Pathology, Reinforcing Blarcamesine Strategy — Mar 20, 2026
Six-Week Blarcamesine Restores Motor Function and Nerve Fiber Growth in Parkinson’s Model — Mar 17, 2026

AVXL Analyst Consensus

2 analysts cover AVXL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.

Common questions about AVXL

Who is trading AVXL stock inside the company?: Recent AVXL insider activity includes Donhauser Peter D.O. bought 2.83K, Thomas Steffen bought 5.00K, MISSLING CHRISTOPHER U sold 73.38K, MISSLING CHRISTOPHER U sold 268.00K, and Skarpelos Athanasios sold 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AVXL?: Yes. Rallies tracks AVXL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AVXL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVXL. It does not provide personalized investment advice.